Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients

• Status: Completed
• Trial end date: 2019-09-18
• Target enrollment: 0
• Participant gender: Female

Summary

Non-interventional, multicenter, prospective, European study to describe the effectiveness of trabectedin + PLD in the treatment of relapsed ovarian cancer (ROC) patients according to SmPC regardless of previous use of an antiangiogenic drug

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PharmaMar
• Treatments: Trabectedin

Criteria

Inclusion Criteria:

• Women aged 18 years or older.

• Presence of platinum-sensitive relapsed ovarian cancer.

• Treatment and treated indication according to local label SmPC and reimbursement for trabectedin and PLD treatment.

• Prior treatment with a minimum of 1 cycle of trabectedin + PLD according to SmPC before inclusion in the study, and no more than 3 previous treatment lines.

• Written informed consent indicating that patients understand the purpose and procedures and are willing to participate in the study.

Exclusion Criteria:

• None